CAR T-cell Therapy in Patients With Renal Dysfunction
This is a prospective, descriptive study designed to assess the feasibility of administering CAR T therapy among patients with moderate to severe renal impairment using dose adjusted lymphodepleting chemotherapy.
Non-hodgkin Lymphoma,B Cell|Multiple Myeloma|Acute Lymphoblastic Leukemia, Adult
DRUG: Fludarabine|DRUG: Cyclophosphamide
Occurrence of CRS, Collection of maximum grade of CRS (based on CTCAE v5) and when this event occurs post CAR T cell therapy infusion, 90 days|Occurrence of ICANS, Collection of maximum grade of ICANs (based on CTCAE v5) and when this event occurs after CAR T cell therapy infusion, 90 days|Occurrence of Cytopenias, Collection of grade 3 or higher (based on CTCAE v5) cytopenias not resolved by Day 30 post CAR T cell infusion, 90 days
This is a prospective, descriptive study designed to assess the feasibility of administering CAR T therapy among patients with moderate to severe renal impairment using dose adjusted lymphodepleting chemotherapy.